AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31527875 — intervention group
Group type: EXPERIMENTAL
Intervention: Underweight children (weight-for-age Z-scores <-2 SD)
Number of subjects: 873
Study 31528836 — intervention group
Group type: EXPERIMENTAL
Intervention: Almond snacking for 8 weeks
Number of subjects: 73
Study 31528836 — intervention group
Group type: COMPARATOR
Intervention: Graham cracker snacking (isocaloric control)
Number of subjects: 73
Study 31528838 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH diet + Captopril (CAP) 25 mg
Number of subjects: 44
Study 31528838 — intervention group
Group type: COMPARATOR
Intervention: Control (CON) diet + Captopril (CAP) 25 mg
Number of subjects: 44
Study 31528838 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH diet
Number of subjects: 44
Study 31529018 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy with a simultaneous integrated boost of radiotherapy dose (50.4 Gy to subclinical areas at risk and 63.0 Gy to the gross tumor and involved nodes, all given in 28 fractions) with concurrent docetaxel and capecitabine or fluorouracil
Number of subjects: 46
Study 31529018 — intervention group
Group type: COMPARATOR
Intervention: Chemoradiotherapy with a simultaneous integrated boost
Number of subjects: 46
Study 31529056 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher concentrations of several-sized VLDL particles and medium- and small-sized HDL particles in women developing GDM (n = 82)
Number of subjects: 357
Study 31529056 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher concentrations of isoleucine and leucine, and GlycA in women developing GDM
Number of subjects: 357
Study 31529056 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher concentration of small-sized HDL particles as a predictive marker for GDM
Number of subjects: 357
Study 31529056 — intervention group
Group type: EXPERIMENTAL
Intervention: Distinct early pregnancy metabolomic profile in women developing GDM
Number of subjects: 357
Study 31529070 — intervention group
Group type: COMPARATOR
Intervention: Insulin tolerance test
Number of subjects: 20
Study 31529070 — intervention group
Group type: COMPARATOR
Intervention: Sodium depletion test (oral administration of 40 mg of furosemide under low sodium diet)
Number of subjects: 20
Study 31529103 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-port thoracoscopic sympathicotomy
Number of subjects: 8
Study 31529136 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower limb injections of abobotulinumtoxinA (1,000 U or 1,500 U)
Number of subjects: 0
Study 31529136 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower and upper limb injections of abobotulinumtoxinA (1,000 U lower limb, 500 U upper limb)
Number of subjects: 0
Study 31529145 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP-treated OSA patients with hypertension
Number of subjects: 41
Study 31529145 — intervention group
Group type: COMPARATOR
Intervention: CPAP-treated OSA patients with normotension
Number of subjects: 41
Study 31529318 — intervention group
Group type: EXPERIMENTAL
Intervention: Bococizumab
Number of subjects: 352
Study 31529511 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low energy diet
Number of subjects: 298
Study 31529511 — intervention group
Group type: COMPARATOR
Intervention: Control (non-PCOS)
Number of subjects: 298
Study 31530099 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial intelligence fitting for cochlear implants
Number of subjects: 0
Study 31530099 — intervention group
Group type: COMPARATOR
Intervention: Manual fitting for cochlear implants
Number of subjects: 0
Study 31530552 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating advanced glycation endproducts (AGEs)
Number of subjects: 555
Study 31530565 — intervention group
Group type: EXPERIMENTAL
Intervention: Various cluster criteria for defining glaucomatous visual field abnormalities
Number of subjects: 384
Study 31530565 — intervention group
Group type: EXPERIMENTAL
Intervention: Definitions requiring abnormalities to be repeatable at the same location
Number of subjects: 384
Study 31530565 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual field cluster criteria
Number of subjects: 384
Study 31530660 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-HIT intervention
Number of subjects: 11
Study 31531798 — intervention group
Group type: EXPERIMENTAL
Intervention: CT colonography (CTC) followed by optical colonoscopy (OC)
Number of subjects: 223
Study 31531798 — intervention group
Group type: COMPARATOR
Intervention: Optical colonoscopy (OC)
Number of subjects: 223
Study 31531798 — intervention group
Group type: COMPARATOR
Intervention: CT colonography (CTC)
Number of subjects: 223
Study 31531823 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischaemia-driven complete coronary revascularisation by percutaneous coronary intervention (PCI)
Number of subjects: 414
Study 31531823 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 414
Study 31531991 — intervention group
Group type: EXPERIMENTAL
Intervention: Menthol-flavoured quit smoking aid, electronically heated menthol-flavoured EC with 0% nicotine
Number of subjects: 16
Study 31531991 — intervention group
Group type: EXPERIMENTAL
Intervention: Menthol-flavoured quit smoking aid, electronically heated menthol-flavoured EC with 5.4% nicotine
Number of subjects: 16
Study 31532016 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal carotenoid levels
Number of subjects: 0
Study 31532016 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal vitamin A levels
Number of subjects: 0
Study 31532016 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal vitamin E levels
Number of subjects: 0
Study 31532522 — intervention group
Group type: EXPERIMENTAL
Intervention: Leydig cell tumors (LCTs)
Number of subjects: 83
Study 31532724 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 2 mg/kg every 3 weeks for up to 24 months
Number of subjects: 24
Study 31532724 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 24
Study 31532833 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (anti-PD-1), administered as part of a Phase II clinical trial, with biopsies taken at baseline and 15-21 days post-dose.
Number of subjects: 0
Study 31533636 — intervention group
Group type: EXPERIMENTAL
Intervention: Pisando Fuerte (PF) intervention, 2-hour sessions delivered in Spanish over 8 weeks
Number of subjects: 24
Study 31533636 — intervention group
Group type: EXPERIMENTAL
Intervention: Pisando Fuerte (PF) intervention
Number of subjects: 24
Study 31533707 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotrimoxazole
Number of subjects: 2
Study 31533707 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin
Number of subjects: 2
Study 31533713 — intervention group
Group type: EXPERIMENTAL
Intervention: Cristal images teleimaging
Number of subjects: 0
Study 31533713 — intervention group
Group type: COMPARATOR
Intervention: Before deployment of Cristal images (2015-2016)
Number of subjects: 0
Study 31533713 — intervention group
Group type: EXPERIMENTAL
Intervention: After deployment of Cristal images (2018-2019)
Number of subjects: 0
Study 31533734 — intervention group
Group type: EXPERIMENTAL
Intervention: Condomless anal intercourse with non-steady partners
Number of subjects: 118
Study 31533759 — intervention group
Group type: EXPERIMENTAL
Intervention: PDA surgical ligation
Number of subjects: 50
Study 31533753 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding (exclusive and non-exclusive)
Number of subjects: 6861
Study 31533753 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding (any 3 month period)
Number of subjects: 6861
Study 31533753 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of exclusive breastfeeding
Number of subjects: 6861
Study 31533771 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab administered subcutaneously at 1 mg/kg body weight, dosage scheduled based on urinary deoxypyridinoline levels.
Number of subjects: 10
Study 31533814 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (RT) for 14 weeks
Number of subjects: 0
Study 31533818 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg intravenously every 3 weeks
Number of subjects: 16
Study 31533828 — intervention group
Group type: EXPERIMENTAL
Intervention: MyDiabetesPlan (an online decision aid)
Number of subjects: 17
Study 31533828 — intervention group
Group type: EXPERIMENTAL
Intervention: Interprofessional shared decision-making (IP-SDM)
Number of subjects: 17
Study 31533828 — intervention group
Group type: EXPERIMENTAL
Intervention: Usability assessment of MyDiabetesPlan
Number of subjects: 17
Study 31533828 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component toolkit and implementation strategy
Number of subjects: 17
Study 31533965 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative fluorescence endoscopy
Number of subjects: 0
Study 31533974 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast MRI
Number of subjects: 299
Study 31533974 — intervention group
Group type: COMPARATOR
Intervention: CT
Number of subjects: 299
Study 31534013 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD0156 (low doses)
Number of subjects: 0
Study 31534013 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD0156
Number of subjects: 0
Study 31534192 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF + plerixafor (G-CSF + P)
Number of subjects: 77
Study 31534380 — intervention group
Group type: EXPERIMENTAL
Intervention: Doctor and pharmacy shopping (Shopping) for opioids
Number of subjects: 164923
Study 31534380 — intervention group
Group type: COMPARATOR
Intervention: Insurance claims data
Number of subjects: 164923
Study 31534773 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal strength training (MST) twice a week for 5 weeks, consisting of 3-4 sets of 4-6 repetitions at ≥85% of 1RM in a squat exercise.
Number of subjects: 33
Study 31534773 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) doing regular pre-season preparations.
Number of subjects: 33
Study 31534782 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep phenotyping through multiomics approaches
Number of subjects: 100
Study 31535129 — intervention group
Group type: EXPERIMENTAL
Intervention: [13C10]retinyl acetate ingestion
Number of subjects: 3
Study 31535135 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight gainers (n = 36)
Number of subjects: 67
Study 31535135 — intervention group
Group type: COMPARATOR
Intervention: Weight stable group (n = 31)
Number of subjects: 67
Study 31535207 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese MS+ group
Number of subjects: 559
Study 31535207 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-obese MS+ group
Number of subjects: 559
Study 31535207 — intervention group
Group type: COMPARATOR
Intervention: Obese MS- group
Number of subjects: 559
Study 31535207 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall analysis
Number of subjects: 559
Study 31535597 — intervention group
Group type: EXPERIMENTAL
Intervention: Biochemically-verified cannabis abstinence
Number of subjects: 70
Study 31536129 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-port robotic surgical system
Number of subjects: 47
Study 31536622 — intervention group
Group type: EXPERIMENTAL
Intervention: Cosyntropin-stimulated AVS
Number of subjects: 1625
Study 31536622 — intervention group
Group type: COMPARATOR
Intervention: Unstimulated AVS
Number of subjects: 1625
Study 31536622 — intervention group
Group type: COMPARATOR
Intervention: Post-adrenalectomy outcomes
Number of subjects: 1625
Study 31537296 — intervention group
Group type: EXPERIMENTAL
Intervention: Local Anesthesia
Number of subjects: 0
Study 31537296 — intervention group
Group type: COMPARATOR
Intervention: General Anesthesia
Number of subjects: 0
Study 31537446 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonparametric tests for comparing immunological Reverse Cumulative distribution curves (RCDCs)
Number of subjects: 0
Study 31537446 — intervention group
Group type: EXPERIMENTAL
Intervention: Rank-based tests
Number of subjects: 0
Study 31537446 — intervention group
Group type: EXPERIMENTAL
Intervention: RCDCs
Number of subjects: 0
Study 31537446 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonparametric tests
Number of subjects: 0
Study 31537486 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib (15 mg twice a day) on a continuous 28-day cycle
Number of subjects: 5
Study 31537565 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid injectable emulsion (two doses)
Number of subjects: 64
Study 31537565 — intervention group
Group type: COMPARATOR
Intervention: Active control (no treatment)
Number of subjects: 64
Study 31537687 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylation-specific multiplex ligation-dependent probe amplification
Number of subjects: 24
Study 31537687 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylation classifier based on nine promoters
Number of subjects: 24
Study 31538078 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramosetron (0.3 mg IV)
Number of subjects: 90
Study 31538078 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline IV)
Number of subjects: 90
Study 31538230 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib (750, 1000, 1250, or 1500 mg daily) plus Bortezomib (0.7, 1.0, 1.3, or 1.6 mg/m²)
Number of subjects: 0
Study 31538605 — intervention group
Group type: EXPERIMENTAL
Intervention: Fitbit Alta HR
Number of subjects: 58
Study 31538605 — intervention group
Group type: EXPERIMENTAL
Intervention: Philips Respironics Actiwatch 2 (AW2) at medium setting (M10)
Number of subjects: 58
Study 31538605 — intervention group
Group type: EXPERIMENTAL
Intervention: Philips Respironics Actiwatch 2 (AW2) at high motion threshold setting (H5)
Number of subjects: 58
Study 31538605 — intervention group
Group type: EXPERIMENTAL
Intervention: Fitbit
Number of subjects: 58
Study 31538606 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurometer current perception threshold (CPT) system at 2,000 Hz
Number of subjects: 32
Study 31538606 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurometer current perception threshold (CPT) system at 250 Hz
Number of subjects: 32
Study 31538606 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurometer current perception threshold (CPT) system at 5 Hz
Number of subjects: 32
Study 31538815 — intervention group
Group type: EXPERIMENTAL
Intervention: Efficacy-toxicity design
Number of subjects: 0
Study 31538815 — intervention group
Group type: COMPARATOR
Intervention: Dose-escalation followed by an expansion cohort
Number of subjects: 0
Study 31538815 — intervention group
Group type: COMPARATOR
Intervention: DE-ECext
Number of subjects: 0
Study 31538818 — intervention group
Group type: EXPERIMENTAL
Intervention: Daromun (intralesional immunocytokine)
Number of subjects: 0
Study 31538818 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 31538944 — intervention group
Group type: EXPERIMENTAL
Intervention: Future Patient Telerehabilitation program
Number of subjects: 0
Study 31538944 — intervention group
Group type: COMPARATOR
Intervention: Traditional cardiac rehabilitation program
Number of subjects: 0
Study 31539467 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily Indacaterol/Glycopyrrolate (IND/GLY)
Number of subjects: 2038
Study 31539582 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient factors: elevated blood pressure (EBP), no familial history, single IA, active smoking
Number of subjects: 1289
Study 31539582 — intervention group
Group type: EXPERIMENTAL
Intervention: Aneurysm factors: size≥5mm, narrow neck, irregular shape, ACA/Acom location
Number of subjects: 1289
Study 31539582 — intervention group
Group type: EXPERIMENTAL
Intervention: Matched pair analysis risk factors: no familial history of aneurysm, narrow neck, active smoking, ACA/Acom location, irregular shape
Number of subjects: 1289
Study 31539757 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-nucleotide polymorphisms (SNPs) rs8187710 (ABCC2) and rs1801131 (MTHFR)
Number of subjects: 59
Study 31539757 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-nucleotide polymorphisms (SNPs) rs3788007 (ABCG1) and rs4148943 (CHST3)
Number of subjects: 59
Study 31539757 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-nucleotide polymorphisms (SNPs) rs2301159 (SLC10A2) and rs2470890 (CYP1A2)
Number of subjects: 59
Study 31540306 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation (PR)
Number of subjects: 0
Study 31540339 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 79
Study 31540339 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study 31540745 — intervention group
Group type: EXPERIMENTAL
Intervention: IL4: rs2243250 genetic variant
Number of subjects: 359
Study 31540834 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheters placed for <3 days
Number of subjects: 127
Study 31540966 — intervention group
Group type: EXPERIMENTAL
Intervention: RNA expression profiles analysis using RNAseq
Number of subjects: 417
Study 31541068 — intervention group
Group type: EXPERIMENTAL
Intervention: Ecological Momentary Assessment (EMA)
Number of subjects: 45
Study 31541204 — intervention group
Group type: EXPERIMENTAL
Intervention: Unrelated peripheral blood stem cell graft (PBSC) with PTCy, tacrolimus, and MMF
Number of subjects: 79
Study 31541204 — intervention group
Group type: COMPARATOR
Intervention: Matched-related bone marrow (BM) grafts with single-agent PTCy
Number of subjects: 79
Study 31541204 — intervention group
Group type: EXPERIMENTAL
Intervention: High prevalence of CD3, NKT, and CD16-CD56+ subpopulations in PBSC grafts
Number of subjects: 79
Study 31541293 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee Control injury prevention exercise programme (IPEP) or Knee Control+
Number of subjects: 8
Study 31541293 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 8
Study 31541381 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib 60-mg daily on a 21-day cycle + trastuzumab every 3 weeks (Cohort 1)
Number of subjects: 36
Study 31541381 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib 60-mg daily on a 21-day cycle (Cohort 2)
Number of subjects: 36
Study 31541381 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib 60-mg daily on a 21-day cycle (Cohort 3)
Number of subjects: 36
Study 31541381 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib 60-mg daily on a 21-day cycle
Number of subjects: 36
Study 31541945 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral panobinostat plus chemotherapy (idarubicin and cytarabine)
Number of subjects: 0
Study 31541945 — intervention group
Group type: COMPARATOR
Intervention: Idarubicin and cytarabine (chemotherapy)
Number of subjects: 0
Study 31542380 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS-guided nCLE characteristics of increased papillary epithelial width (cut-off ≥50 μm)
Number of subjects: 26
Study 31542380 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS-guided nCLE characteristics of increased papillary epithelial darkness (cut-off ≤90 pixel intensity)
Number of subjects: 26
Study 31542380 — intervention group
Group type: EXPERIMENTAL
Intervention: Interobserver agreement for width
Number of subjects: 26
Study 31542380 — intervention group
Group type: EXPERIMENTAL
Intervention: Interobserver agreement for darkness
Number of subjects: 26
Study 31542526 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin or doxorubicin followed by trastuzumab
Number of subjects: 362
Study 31542526 — intervention group
Group type: COMPARATOR
Intervention: Trastuzumab alone
Number of subjects: 362
Study 31542526 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in E/e' ratio
Number of subjects: 362
Study 31542729 — intervention group
Group type: EXPERIMENTAL
Intervention: Round facemasks with an external diameter of 50 mm
Number of subjects: 102
Study 31542729 — intervention group
Group type: EXPERIMENTAL
Intervention: Round facemasks with an external diameter of 42 mm
Number of subjects: 102
Study 31542729 — intervention group
Group type: EXPERIMENTAL
Intervention: Round facemasks with an external diameter of 60 mm
Number of subjects: 102
Study 31542729 — intervention group
Group type: EXPERIMENTAL
Intervention: 2D images
Number of subjects: 102
Study 31542729 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D images
Number of subjects: 102
Study 31542738 — intervention group
Group type: EXPERIMENTAL
Intervention: Polso National Early Warning Score measurements
Number of subjects: 300
Study 31542738 — intervention group
Group type: COMPARATOR
Intervention: Manual measurements
Number of subjects: 300
Study 31542743 — intervention group
Group type: EXPERIMENTAL
Intervention: Resilience and quality of life assessment using EORTC QLQ-C30, EORTC QLQ-H&N35, EORTC QLQ-BN20, and Wagnild and Young's 14-item scale.
Number of subjects: 500
Study 31542743 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation analysis using Pearson or Spearman rank correlation coefficients.
Number of subjects: 500
Study 31543165 — intervention group
Group type: EXPERIMENTAL
Intervention: DCB
Number of subjects: 1069
Study 31543165 — intervention group
Group type: COMPARATOR
Intervention: PTA
Number of subjects: 1069
Study 31543165 — intervention group
Group type: EXPERIMENTAL
Intervention: DCB (propensity-matched)
Number of subjects: 1069
Study 31543165 — intervention group
Group type: COMPARATOR
Intervention: PTA (propensity-matched)
Number of subjects: 1069
Study 31543859 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Modular Rebalancing System and Visual Cueing
Number of subjects: 0
Study 31543859 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 31543982 — intervention group
Group type: EXPERIMENTAL
Intervention: Team-Based Goals and Incentives (TBGI) intervention
Number of subjects: 1300
Study 31544065 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal Pemetrexed
Number of subjects: 0
Study 31544817 — intervention group
Group type: EXPERIMENTAL
Intervention: MEDI4276 (antibody-drug conjugate)
Number of subjects: 0
Study 31544817 — intervention group
Group type: EXPERIMENTAL
Intervention: MEDI1498 (de-acetylated MEDI4276)
Number of subjects: 0
Study 31544817 — intervention group
Group type: EXPERIMENTAL
Intervention: MEDI4276 and MEDI1498
Number of subjects: 0
Study 31544817 — intervention group
Group type: EXPERIMENTAL
Intervention: MEDI4276
Number of subjects: 0
Study 31544944 — intervention group
Group type: COMPARATOR
Intervention: Transgender Males (TM)
Number of subjects: 69
Study 31544944 — intervention group
Group type: COMPARATOR
Intervention: Transgender Females (TF)
Number of subjects: 69
Study 31544947 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment (surgery or medical treatment)
Number of subjects: 18
Study 31545113 — intervention group
Group type: EXPERIMENTAL
Intervention: Selinexor in combination with decitabine
Number of subjects: 0